

SmartPA Criteria Proposal

Drug/Drug Class:	Megestrol Acetate Clinical Edit
First Implementation Date:	August 12, 2010
Proposed Date:	March 17, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of megestrol acetate

Why Issue Selected: Megestrol is a synthetic oral progestin with slight glucocorticoid and mineralocorticoid activity. Megestrol acetate tablets are indicated for palliative treatment of advanced carcinoma of the breast or endometrium. The suspension is indicated for the treatment of anorexia, cachexia, or unexplained significant weight loss in patients with acquired immunodeficiency syndrome (AIDS). Due to the possible adverse events and specific approved indications, MO HealthNet will impose clinical criteria to ensure appropriate utilization of megestrol acetate.

Program-Specific Information:	Date Range FFS 1-1-2021 to 12-31-2021			
	Drug	Claims	Spend	Avg Spend per Claim
	MEGESTROL 40 MG/ML SUSP	506	\$18,468.42	\$36.49
	MEGESTROL 625 MG/5 ML SUSP	7	\$1,429.97	\$204.28
	MEGESTROL 20 MG TABLET	136	\$2490.98	\$18.31
	MEGESTROL 40 MG TABLET	514	\$12,567.87	\$24.45

Type of Criteria: Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit

Data Sources: Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Megestrol acetate
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- Participant is compliant with current therapy (90 out of 120 days) **OR**
- Claim is for megestrol 40 mg/ml suspension or tablets **OR**
- Claim is for megestrol 625 mg/5 ml suspension:

- Documented diagnosis of malignant neoplasm of the breast, uterus, or ovaries or HIV/AIDS with cachexia **AND**
- Documented therapeutic trial of megestrol 40 mg/ml suspension or tablets in the past 2 years

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Participant is currently pregnant
- Claim exceeds maximum daily dosage limitations:

Drug Description	Generic Equivalent	Max Dose Per Day
MEGESTROL 40 MG/ML SUSP	MEGESTROL ACETATE	800 mg
MEGESTROL 625 MG/5 ML SUSP	MEGESTROL ACETATE	625 mg
MEGESTROL 20 MG TABLET	MEGESTROL ACETATE	800 mg
MEGESTROL 40 MG TABLET	MEGESTROL ACETATE	800 mg

Required Documentation

Laboratory Results:
 MedWatch Form:

Progress Notes:
 Other:

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
 Rule Type: CE

Default Approval Period

3 months

References

- Facts & Comparisons. Megestrol Oral. Accessed February 2, 2022.
- Clinical Pharmacology. Megestrol. Accessed February 2, 2022.